Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Oct. 02, 2020

Quarterly Financial Information Disclosure [Abstract]


	Fiscal Year 2020
(In millions, except per share amounts)	First Quarter		Second Quarter)(3)		Third Quarter (2)		Fourth Quarter (1)		Total Year
Total revenues	$	828.9	$	794.5	$	694.3	$	850.5	$	3,168.2
Gross margin	$	366.8	$	337.2	$	298.5	$	374.7	$	1,377.2
Net earnings	$	88.9	$	43.1	$	60.9	$	76.5	$	269.4

Net earnings attributable to Varian	$	88.2	$	43.2	$	61.2	$	76.6	$	269.2



Net earnings per share - basic	$	0.97	$	0.48	$	0.67	$	0.84	$	2.96



Net earnings per share - diluted	$	0.96	$	0.47	$	0.67	$	0.83	$	2.94

	Fiscal Year 2019
(In millions, except per share amounts)	First Quarter (5)		Second Quarter		Third Quarter (6)		Fourth Quarter (7)		Total Year
Total revenues	$	741.0	$	779.4	$	825.8	$	878.9	$	3,225.1
Gross margin	$	316.1	$	318.2	$	351.4	$	384.6	$	1,370.3
Net earnings (loss)	$	103.9	$	88.4	$	29.5	$	70.4	$	292.2

Net earnings attributable to Varian	$	103.2	$	88.6	$	29.4	$	70.7	$	291.9




Net earnings (loss) per share - basic	$	1.13	$	0.97	$	0.32	$	0.78	$	3.21



Net earnings (loss) per share - diluted	$	1.12	$	0.96	$	0.32	$	0.77	$	3.18

(1)In the fourth quarter of fiscal year 2020, net earnings includes a $14.8 million in net gains on the Company's equity investments, $10.9 million in litigation charges and legal cost and an $8.6 million impairment charge related to the Company's available-for-sale investments.

(2)In the third quarter of fiscal year 2020, net earnings includes a $25.7 million gain on equity investments, $13.9 million in restructuring charges and a $9.2 million impairment charge related to the Company's available-for-sale investments.

(3)In the second quarter of fiscal year 2020, net earnings includes a $40.5 million impairment charge related to the Company's CPTC Loans and the release of $8.9 million in contingent consideration liabilities.

(4)In the first quarter of fiscal year 2020, net earnings includes $8.8 million charge to acquisition-related expenses due to an increase to the fair value of contingent consideration related to an acquisition.

(5)In the first quarter of fiscal year 2019, net earnings includes a $22.0 million gain on the sale of our investment in Augmenix.

(6)In the third quarter of fiscal year 2019, net earnings includes a $50.5 million goodwill impairment charge related to the Company's Proton Solutions business and a $20.8 million charge associated with the write-off of in-process R&D related to an acquisition.

(7)In the fourth quarter of fiscal year 2019, net earnings includes an $18.6 million charge to acquisition-related expenses due to an increase to the fair value of contingent consideration related to an acquisition.